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Objective: To explore the effects of SERPINB3 administration in murine lupus models
with a focus on lupus-like nephritis.
Methods: 40 NZB/W F1 mice were subdivided into 4 groups and intraperitoneally
injected with recombinant SERPINB3 (7.5 µg/0.1mL or 15 µg/0.1mL) or PBS (0.1mL)
before (group 1 and 2) or after (group 3 and 4) the development of proteinuria (≥100
mg/dl). Two additional mice groups were provided by including 20 MRL/lpr mice which
were prophylactically injected with SERPINB3 (10 mice, group 5) or PBS (10 mice, group
6). Time of occurrence and levels of anti-dsDNA and anti-C1q antibodies, proteinuria and
serum creatinine, overall- and proteinuria-free survival were assessed in mice followed up
to natural death. Histological analysis was performed in kidneys of both lupus models.
The Th17:Treg cell ratio was assessed by flow-cytometry in splenocytes of treated and
untreated MRL/lpr mice. Statistical analysis was performed using non parametric tests
and Kaplan-Meier curves, when indicated.
Results: Autoantibody levels and proteinuria were significantly decreased and
time of occurrence significantly delayed in SERPINB3-treated mice vs. controls. In
agreement with these findings, proteinuria-free and overall survival were significantly
improved in SERPINB3-treated groups vs. controls. Histological analysis demonstrated
a lower prevalence of severe tubular lesions in kidneys of group 5 vs. group 6.
SERPINB3-treated mice showed an overall trend toward a reduced prevalence of severe
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lesions in both strains. Th17:Treg ratio was significantly decreased in splenocytes of
MRL/lpr mice treated with SERPINB3, compared to untreated control mice.
Conclusions: SERPINB3 significantly improves disease course and delays the onset
of severe glomerulonephritis in lupus-prone mice, possibly inducing a more tolerogenic
immune phenotype.
Keywords: systemic lupus erythematosus, SERPINB3, survival, lupus nephritis, apoptosis, Treg
INTRODUCTION
Development of systemic lupus erythematosus (SLE) is driven by
several immunological abnormalities, including altered function
of normally protective molecules and deregulated apoptosis
(1, 2).
SERPINB3 belongs to SERPINs (SERin Protease INhibitors)
superfamily, a group of highly conserved proteins with enzymatic
anti-protease activity orchestrating organ development, cell
survival and broad tissue homeostasis (3, 4). Despite its acronym,
SERPINB3 is a cystein protease inhibitor whose expression
is physiologically broad among epithelial tissues in the body
and is deregulated in a variety of epithelial squamous and
nonsquamous carcinomas, where it is involved in enhanced cell
survival (5). Indeed, SERPINB3 confers resistance to apoptosis
induced by different stimuli, including ultraviolet radiation
(6), chemotherapeutic drugs (7) and tumor necrosis factor
(TNF)-alpha (8). The prominent mechanism of inhibition
is thought to be upstream caspase 3 activation, preventing
cytochrome c release frommitochondria in response to oxidative
stress conditions (9). Recent findings indicate that a fraction
of SERPINB3 binds respiratory Complex I in the inner
mitochondrial compartments, inhibiting reactive oxygen species
(ROS) generation and hindering the opening of the permeability
transition pore, a point of no return in cell commitment to
death (7).
In addition, decreased phosphorylation of the proapoptotic
molecule p38 MAPK (mitogen-activated protein kinase)
or of the active forms MKK3/6 was shown in engineered
293T cells overexpressing SERPINB3, thus suggesting
an additional mechanism of apoptosis inhibition (6).
Importantly, the antiapoptotic potential of SERPINB3 is
at least in part independent on its anti-cystein protease
activity, as other kinds of kinases are still inhibited by
SERPINB3 binding (10). On the other hand, SERPINB3
was found to promote endoplasmic reticulum-stress
induced apoptosis, thus exerting a double-faced effect on
cell viability (11).
SERPINB3 was shown to be expressed on CD27+ B
lymphocyte surface of healthy donors, while it was absent on
CD27+ cells of lupus patients (12). Interestingly, its expression
can be down-regulated by interferon alpha (IFNα) which is
up-regulated in SLE (12). Moreover, SERPINB3 determines
increased production of transforming growth factor (TGF)-β and
down-regulation of miR-146b-5p miRNA, implicated in TGF-
β pathway inhibition (13, 14), thus suggesting a globally anti-
inflammatory activity.
Deregulated apoptosis and impaired removal of cellular debris
are known to play a role in SLE and lupus nephritis. Therefore,
decreased or absent expression of a molecule deeply involved
in the modulation of cell viability and in immune modulation
represented the rationale to explore the effects of SERPINB3
restoration in murine models of SLE.
MATERIALS AND METHODS
Animal Models and Study Design
New Zealand Black/White (NZB/NZW) F1 Mice
New Zealand Black/White (NZB/NZW) F1 mice, a well
characterized model of lupus-like glomerulonephritis, were
treated with recombinant SERPINB3, produced as previously
described (15), either before (preventive approach) or after
(therapeutic approach) the development of proteinuria.
Preventive approach
Twenty 12-week-old NZB/NZW F1 female mice (Harlan
Laboratories, Envigo RMS, UD, Italy) were subdivided into 2
groups of 10 mice each and intraperitoneally injected with a total
volume of 100 µl consisting of 7.5 µg of SERPINB3 in 100 µl of
phosphate buffered saline (PBS, vehicle) (group 1) or 100 µl of
vehicle (group 2). Mice were injected twice a week, starting from
the 17th week of age, and bred until natural death, except three
mice from both groups which were sacrificed at week 27. Kidneys
of mice sacrificed at week 27 (3 belonging to group 1 and 3 to
group 2) were harvested for histological comparison.
Therapeutic approach
Twenty 12-week-old NZB/NZW F1 female mice were subdivided
into 2 groups of 10 mice each and were intraperitoneally injected
with a total volume of 100 µl consisting of 15 µg of SERPINB3
in 100 µl of vehicle (group 3) or 100 µl of vehicle alone (group
4). Mice were injected twice a week, starting after development of
proteinuria ≥100 mg/dl, and bred until natural death.
Urine samples were collected from all mice and proteinuria
was evaluated weekly.
Blood samples were collected from the caudal vein at the 17th,
21st, 25th, 28th, 32rd week of age, and at death.
Kidneys from 6 mice were harvested at death for histological
examination, but were not included in the comparative analysis.
MRL/lpr Mice
MRL/lpr mice display an impaired Fas function due to
a recessive autosomal mutation named lpr (standing for
lymphoproliferation). Descending abnormalities in the
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apoptotic process lead to diverse clinical features, mostly
depending on dysregulated CD4+ T cell and B cell function
including widespread lymphadenopathy with double negative
T cell infiltrates increasing with disease severity, early severe
proliferative nephritis leading to death between 3 and 7 months
of age, severe necrotizing arteritis, neuropsychiatric symptoms
and erosive polyarthritis (16).
MRL/lpr mice were treated with recombinant
SERPINB3 before the development of proteinuria in
order to explore the preventive approach in a multiorgan
system.
Twenty 8-week-old MRL/lpr female mice (Harlan
Laboratories) were subdivided into 2 groups of 10 mice
each and were intraperitoneally injected with a total volume of
100 µl consisting of 7.5 µg of SERPINB3 in 100 µl of vehicle
(group 5) or 100 µl of vehicle (group 6), as controls. Mice were
injected twice a week, starting from the 9th to the 18th week of
age.
Urine samples were collected and proteinuria was evaluated
weekly.
Blood samples were collected from the caudal vein 3
weeks apart, starting from the 9th week of age, until mice
sacrifice at week 13 (6 mice) and 16–18 (6 mice). Time for
sacrifice was chosen a priori, taking into account the age
at which the disease is known to be full-blown (around 4
months).
Kidneys were harvested from 12 mice at sacrifice for
histological analyses.
This study was approved by the National Institutional Animal
Care and Use Committee.
Recombinant SERPINB3 Synthesis
SERPINB3 cDNA was obtained as previously described
(15). Briefly, first strand cDNA was synthesized by nested
polymerase chain reaction (PCR), using 2 pairs of specific
oligonucleotide primers (Invitrogen - Primer out Forward 5′-
CACAGGAGTTCCAGATCACATCGAG-3′ Primer out Reverse
5′-CTGGAAGAAAAAGTACATTTATATGTGGGC-3′ Primer
out Forward 5′-CACCATGAATTCACTCAGTGAAGCCA-3′
Primer out Reverse 5′-ATTGCATCTACGGGGATGAG-3′).
The obtained PCR fragment was inserted into mammalian
expression vectors and propagated into E. Coli competent
cells. Recombinant SERPINB3 protein was characterized on
retained dialyzed and cation-exchange chromatography purified
soluble fraction from crude bacterial extract by SDS-PAGE
with Coomassie blue staining (15). To remove endotoxins, the
recombinant SERPINB3 protein was loaded into a 1mL high-
capacity endotoxin removal spin column (Pierce Biotechnology,
Rockford IL, USA) following the manufacturer’s protocol. The
processed protein was collected by centrifugation at 500 × g
for 5min in the endotoxin-free tube. Endotoxin levels were
assessed using Endosafe portable test system (Charles River
Laboratories) based on the Limulous amoebocyte lysate (LAL)
method. The sensitivity of the assay was 0.05 EU/mL and
SERPINB3 preparation used in the study had undetectable
endotoxin levels.
Evaluation of Clinical Variables:
Proteinuria, Serum Creatinine, and Survival
Disease progression was monitored by weekly urine sample
collection, in order to evaluate proteinuria levels, using multi-
reactive strips (Siemens) and expressed as mg/dl. Proteinuria
was evaluated according to the manufacturer: negative, slight
positive, positive:+= 30 mg/dl,++= 100 mg/dl,+++= 300
mg/dl, and++++≥2,000 mg/dl albumin. Traces of proteinuria
were defined as 15 mg/dl.
Renal function wasmonitored through serum creatinine levels
(µmol/L) that were evaluated on blood samples withdrawn
every 3 weeks starting from week 9 in MRL/lpr mice and
from week 17 in NZB/W F1 mice. Creatinine assessment
was carried out on Cobas 8000 (Roche Diagnostics) using
an enzymatic method, traceable to Isotope Dilution Mass
Spectrometry (IDMS) reference procedure.
Disease-free and overall survival were evaluated in all mice.
Proteinuria-free survival was defined as <300 mg/dl, according
to manufacturer’s instruction, as the threshold of 300 mg/dl
designates a frank positivity.
Measurement of Serum Autoantibodies
Serum levels of mouse IgG anti-C1q and anti-dsDNA antibodies
were evaluated by standardized home-made ELISA tests as
previously described (17).
Briefly, for anti-C1q antibodies, plates were coated with C1q at
a concentration of 5µg/ml. Sera were added in duplicate diluted
1:4 in 1% BSA/PBS with 1MNaCl, to prevent immunocomplexes
(ICs) formation. Alkaline phosphatase-conjugated goat anti-
mouse IgG was added at the dilution of 1:10,000 in 1% BSA/PBS
with 1M NaCl. Finally, p-nitrophenyl phosphate was added.
The plates were read at 405 nm and optical density (OD) 0.287
was chosen as cut-off value. For anti-dsDNA antibodies, plates
were coated following 3 steps: addition of poly-L-lysin at a
concentration of 10µg/ml, in order to catch the DNA; then
addition of calf fetal dsDNA at a concentration of 25µg/ml;
finally, addition of poly-L-glutamate at a concentration of
5µg/ml in order to neutralize the free negative charges of DNA.
Sera were added in duplicates diluted 1:100 in 1% BSA/TBS.
Alkaline phosphatase-conjugated goat anti-mouse IgGwas added
at the dilution of 1:10,000 in 1% BSA/TBS. Finally, p-nitrophenyl
phosphate was added. The plates were read at 405 nm and
OD 0.233 was chosen as cut-off value. Since a calibrator for
murine anti-C1q and anti-dsDNA autoantibody quantification is
not commercially available nor feasibly realizable, autoantibody
levels were expressed as OD units.
ELISA reagents were purchased from Sigma, St Louis, USA;
ELISA plates were purchased by Nalgene Nunc, New York, USA.
Histopathological Analysis
Six NZB/WF1 mice sacrificed at week 27 underwent histological
comparison (three from group 1 and three from group 2).
Kidneys of 12 out of 20 Mrl/lpr mice were harvested for
histological analysis and comparison; six out of 12 mice analyzed
had been sacrificed at week 13 and 6 at week 16–18.
Renal sections as thin as 3µm (microtome Leica RM 2145)
underwent histopathological evaluation by optical microscopy,
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focusing on renal functional compartments (glomeruli, tubuli,
interstitium, vessels). A minimum of 8 glomeruli per sample was
required.
In order to properly evaluate different renal compartments,
specific histological stainings were used. Samples were fixed
in formalin 10% and embedded in paraffine and then stained
by Hematoxyline-Eosin (HE), Periodic Acid Schiff (PAS), Acid
Fuchsin Orange G (AFOG), Masson Trichrome staining (TRIC)
and Periodic Acid Schiff Methanamine (PASM).
Renal sections were then screened by experienced pathologists
in a blinded fashion for presence of glomerular lesions
(glomerulosclerosis and mesangial hyperplasia), perivascular
inflammation and tubular lesions (tubular dilation and presence
of casts), according to a semiquantitative score from 0−1
(no/mild involvement) to 4–5 (very high involvement), as
detailed in Supplementary Table 1 [courtesy of Prof. Susan
Westmoreland, DVM-ABBVIE Pharmaceuticals; IL, USA and
(18)].
Isolation of T Lymphocytes From MRL/lpr
Mice
SERPINB3-treated and vehicle-treated MRL/lpr mice were
sacrificed at 13 and 16–18 weeks of age. The spleens were
removed and dissociated in RPMI medium supplemented
with 50mM HEPES and 10% fetal bovine serum. The cell
suspension was passed through a 70-µm strainer, and cells were
collected by centrifugation at 300 g for 5min. Erythrocytes
were lysed by incubating the cells in red blood cell lysis buffer
(eBiosciences) at room temperature for 5min. T lymphocytes
were then isolated using the EasySepTM mouse T cells isolation
kit (StemCellTM technologies) following the manufacturer’s
instructions.
Flow Cytometry Analysis
CD4+ CD25+ Foxp3+ regulatory T (Treg) cells are important
regulators of immune response and the imbalance between Treg
cells and T helper (Th)17 cells has been already described in
a number of different inflammatory and autoimmune diseases
(19).
The Th17:Treg ratio in T cells isolated from spleen of
SERPINB3-treated and vehicle-treated MRL/lpr mice was
determined by flow cytometry analysis. Single-cell suspensions
were prepared from the collected splenocytes and incubated with
APC-conjugated anti-mouse CD3, peridinin-chlorophyll
proteins (PerCP Cy5.5)-conjugated anti-mouse CD4,
phycoerythrin (PE)–conjugated anti-mouse CD25, FITC–
conjugated anti-mouse FoxP3, PE-conjugated anti-mouse
interleukin (IL)-17, or their respective isotype controls, for
evaluation of T cell subsets. Staining for FoxP3 was conducted
using an eBioscience FoxP3 staining kit. Cells were washed
and analyzed using FACSCanto system (Becton Dickinson
Immunocytometry Systems).
For detection of Th17 cells, T cells (1 × 106 cells/well)
were incubated with 50 ng/ml phorbol myristate acetate and
1µg/ml ionomycin (Sigma) in the presence of brefeldinA
5µg/ml (Sigma) for 5 h, before intracellular staining. Analyses
were performed using FlowJo software (Tree Star).
Data were expressed as the % mean of positive cells ± SD
(standard deviation).
Statistical Analyses
The ELISA results for all autoantibodies were expressed as mean
OD of the duplicates of each serum. The optimal antibody cut-off
values for anti-C1q and anti-dsDNAwere calculated as mean OD
plus 1 SD of the samples of mice before the development of traces
of proteinuria (15 mg/dl). Autoantibody levels were expressed as
median (min-max) of the mean OD of the double of every serum.
The differences between groups were analyzed using
Mann-Whitney U test for nonparametric continuous
variables; proteinuria-free survival rate (proteinuria <300
mg/dl) and survival rates were evaluated by Kaplan-Meyer
method using Mantel-Cox test for comparison. Analysis
of covariance during time was calculated by ANOVA for
repeated measures in MRL/lpr mice sacrificed at discrete time
points. Within-group contrasts were performed according
to Bonferroni’s method. Results of ANOVA are presented
reporting 3 F test values, namely FG for grouping factor,
FT for time, and FGxT for the interaction between time and
grouping factors. Chi-squared test was used for histological
comparison. Flow cytometry data were analyzed by Student’s
t-test for independent samples. IBM SPSS Statistics 22 for
Windows software (IBM SPSS Inc., USA) was used for
calculations. A p value ≤0.05 was considered statistically
significant.
RESULTS
Autoantibody Serum Levels
Preventive SERPINB3 Treatment in NZB/NZW F1
Mice
SERPINB3-treatedmice (group 1) developed anti-C1q antibodies
significantly later and at lower levels than control mice (group 2).
Anti-C1q antibodies were detected in mice of group 1 starting
from the 25th week of age, while in group 2 from the 21st week
of age (Figure 1A). The difference between group 1 and group 2
was statistically significant at weeks 21, 25, 28, and 32 (p< 0.0001
for all time points).
A similar course was observed for anti-dsDNA antibodies, as
mice of group 1 developed anti-dsDNA later and at significantly
lower levels than group 2. Anti-dsDNA antibodies were detected
in group 1 starting from the 28th week of age, while in group 2
they became detectable from the 21st week of age (Figure 1B).
The difference between group 1 and group 2 was statistically
significant at weeks 21, 25, and 28 (p < 0.0001 for all time
points).
Preventive SERPINB3 Treatment in MRL/lpr Mice
SERPINB3-treated MRL/lpr mice (group 5) developed anti-C1q
antibodies significantly later and at lower levels than control
mice (group 6) (FG = 43.70, p < 0.0001; FT = 406.10,
p < 0.0001; FGxT = 12.93, p < 0.0001). Anti-C1q antibodies
were detected in mice of group 5 starting from the 15th
week of age, while in group 6 from the 12th week of age
(Figure 1C). The difference between group 5 and group 6
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FIGURE 1 | Serum autoantibody levels in SERPINB3-treated and vehicle-treated mice: anti-C1q (A) and anti-dsDNA (B) in NZB/NZW F1 mice (preventive approach);
anti-C1q (C) and anti-dsDNA (D) in MRL/lpr mice. Serum dilution for anti-C1q antibody determinazion: 1:4; serum dilution for anti-dsDNA antibody determination:
1:100. The dotted-lines represent the respective antibody cut-off levels. The values are expressed as median (min-max) OD for autoantibodies. Anti-C1q, antibodies
directed to the complement C1q component; Anti-dsDNA, antibodies directed to the double stranded DNA; OD, optical density.
was statistically significant at weeks 15 (p = 0.011) and 18
(p= 0.001).
Mice of group 5 developed anti-dsDNA antibodies later and
at lower levels than mice of group 6 (FG = 22.05, p < 0.0001;
FT = 281.99, p < 0.0001; FGxT = 3.05, p = 0.035; Figure 1D).
Indeed, while at week 12 anti-dsDNA antibodies were detectable
in all mice from group 6, they occurred only in one mouse
from group 5. The difference between group 5 and group 6 was
statistically significant at weeks 12 (p < 0.0001), 15 (p = 0.006),
and 18 (p= 0.046).
Therapeutic SERPINB3 Treatment in NZB/NZW F1
Mice
Anti-C1q and anti-dsDNA antibody levels were lower in
SERPINB3-treated NZB/NZW F1 mice (group 3) vs. control
mice (group 4), with significant differences in median OD at
week 28 for anti-C1q (p = 0.002) and at weeks 28 and 32
for anti-dsDNA antibodies (p < 0.0001 for both) as shown in
Figures 2A,B.
Renal Variables, Proteinuria-Free, and
Global Survival Rates in Mice
Proteinuria levels were expressed in mg/dl as median (min-max)
and overall results are reported in Table 1.
Preventive SERPINB3 Treatment in NZB/NZW F1
Mice
SERPINB3-treated mice (group 1) developed proteinuria
later and at lower levels than control mice (group 2).
Indeed, 6 (60%) mice in group 1 developed traces of
proteinuria at the 25th week of age and the remaining 4
at the 27th week of age, whereas all mice from group 2
developed proteinuria within week 25. At the 27th week of
age, 10% of group 1 mice showed proteinuria levels ≥300
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FIGURE 2 | Comparison of anti-C1q (A) and anti-dsDNA (B) autoantibody levels between SERPINB3-treated (light gray bars) and vehicle-treated NZB/NZW F1 (dark
gray bars) mice in the therapeutic approach at 28 and 32 weeks of treatment, respectively. Antibody levels are expressed as the median (min-max) of the mean OD of
the double of every serum. OD, optical density; Anti-C1q, antibodies against complement fragment 1; Anti-dsDNA, antibodies against double stranded DNA.
TABLE 1 | Comparison of proteinuria between SERPINB3-treated and
vehicle-treated NZB/NZW F1 mice (preventive and therapeutic approaches) and
MRL/lpr mice.
NZB/W F1 mice SERPINB3-treated Vehicle-treated p
PREVENTIVE APPROACH
Week 17 0 (0–0) 0 (0–0) n.s.
Week 21 0 (0–0) 15 (0–15) 0.023
Week 23 0 (0–0) 15 (0–2000) 0.001
Week 25 15 (0–100) 23 (15–2000) n.s.
Week 27 30 (15–300) 2000 (15–2000) n.s.
Week 29 65 (15–300) 2000 (100–2000) 0.036
Week 33 300 (30–2000) 2000 (300–2000) n.s.
THERAPEUTIC APPROACH
Week 17 0 (0–0) 0 (0–0) n.s.
Week 21 0 (0–15) 0 (0–0) n.s.
Week 23 30 (15–30) 15 (0–15) 0.010
Week 25 30 (30–100) 15 (0–300) 0.045
Week 27 100 (100–100) 15 (0–300) n.s.
Week 29 100 (15–2000) 165 (15–2000) n.s.
Week 33 30 (15–2000) 300 (100–2000) n.s.
MRL/lpr MICE (PROPHYLACTIC APPROACH)
w9 0 (0–0) 0 (0–0) n.s.
w12 15 (0–30) 100 (15–100) 0.001
w15 100 (30–300) 100 (100–300) n.s.
w18 100 (100–2000) 300 (300–2000) 0.008
Proteinuria is expressed in mg/dl as median (min-max). NZB/WF1, New Zealand
Black/White first generation; n.s., not significant.
mg/dl vs. 90% of group 2 mice. Difference of proteinuria
between group 1 and group 2 was significant at weeks 21
(p = 0.023), 23 (p = 0.001), and 29 (p = 0.036), as shown in
Table 1.
Proteinuria-free survival rate (proteinuria <300 mg/dl) was
significantly higher in group 1 than in group 2 mice (p = 0.002)
(Figure 3A). At the 31st week of age, 50% of mice in group 1 had
proteinuria levels ≥300 mg/dl, compared with 90% in group 2;
the last mouse of group 1 developed proteinuria ≥300 mg/dl at
the 44th week of age and the last of group 2 at the 33rd week of
age (Figure 3A).
Accordingly, global survival rate was significantly higher in
group 1 than in group 2 mice (p = 0.001) (Figure 3B). In group
2, 50% of mice died within the 26th week of age while none of
SERPINB3-treated mice died within this time frame. At the 36th
week of age, 50% of group 1, but none of the mice of group 2,
were still alive. The last deaths in the SERPINB3-treated group
occurred in three 45-week-old mice (Figure 3B).
Notably, all mice brought to natural death died after
developing the maximum detectable levels of proteinuria (≥300
mg/dl).
No significant difference was found at any time point in
creatinine serum levels between groups (data not shown).
Therapeutic SERPINB3 Treatment in NZB/NZW F1
Mice
Mice were treated between week 24 and 27, i.e., after occurrence
of proteinuria≥100 mg/dl. At the 25th week of age, 40% of mice
of group 3 (SERPINB3 treated) showed proteinuria levels ≥300
mg/dl vs. 100% of mice of group 4 (controls). Proteinuria median
levels were lower in group 3 than in group 4 mice starting from
week 29, despite not reaching statistical significance.
Proteinuria-free survival rate (proteinuria <300 mg/dl) was
significantly higher in group 3 than in group 4 (p = 0.014)
(Figure 3C). At the 25th week of age, none of the mice
in group 3 had proteinuria levels ≥300 mg/dl, compared
with 50% of mice in group 4. The last mouse from group
3 developed proteinuria ≥300 mg/dl at the 42nd week of
age and the last of group 4 at the 32nd week of age
(Figure 3C).
Global survival rate was significantly higher in group 3 than
in group 4 mice (p = 0.009) (Figure 3D). In group 4, 60% of
mice died within the 26th week of age vs. 0 of SerpinB3-treated
mice. At the 36th week of age, 30% of group 3 mice, but none
of the mice of group 4, were still alive. The last 2 mice in the
SERPINB3-treatedmice died at the 45th week of age (Figure 3D).
Also in this case, all mice died after developing the maximum
detectable levels of proteinuria (≥300 mg/dl) and no significant
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FIGURE 3 | Proteinuria free survival rates (<300 mg/dl) and overall survival rates in SERPINB3-treated and vehicle-treated NZB/NZW F1 mice in the preventive
approach (A,B) and in the therapeutic approach (C,D).
difference between groups was found in creatinine serum levels
at any time point (data not shown).
Preventive SERPINB3 Treatment in MRL/lpr Mice
SERPINB3-treated mice (group 5) developed proteinuria later
and at lower levels than control mice (group 6) (FG = 3.93,
p < 0.0001; FT = 10.04, p < 0.0001; FGxT = 2.32, p = 0.084).
Difference between group 5 and group 6 was significant at
weeks 12 (p = 0.001) and 18 (p = 0.008) (Table 1). Indeed,
3 (30%) mice from group 5 developed traces of proteinuria
starting from the 12th week of age, whereas all mice of group
6 developed traces of proteinuria within this week. At the 15th
week of age, only 1 (10%) mouse of group 5 showed proteinuria
levels ≥300 mg/dl vs. 3 (30%) of group 6. At the time of
programmed sacrifice at week 16–18 only 2 (20%) mice of
group 5 developed proteinuria ≥300 mg/dl vs. 100% of control
mice.
No significant difference was found at any time point in
creatinine serum levels between groups (data not shown).
Histological Analysis
Both mice strains develop a lupus-like nephritis.
Only organs harvested from mice sacrificed at given
timepoints were included in the analysis.
Actual scores of histological lesions among sacrificed
littermates are reported in Supplementary Table 2.
Among MRL/lpr mice sacrificed at week 13, no
significant difference was found in glomerular, tubular
or interstitial lesions between treated and control mice,
though the percentage of mice showing severe glomerular
lesions (score 5) was higher in group 6 vs. group 5
(33% vs. 0).
AmongMRL/lprmice sacrificed at week 16–18, severe tubular
lesions (score 4) were found to be significantly more prevalent in
group 6 vs. group 5 (p = 0.014). Severe glomerular lesions were
found to be comparable in group 5 vs. group 6. No difference was
found in severity of perivascular inflammation.
Concerning NZB/W F1 mice sacrificed at week 27, prevalence
of severe glomerular and tubular lesions were comparable among
group 1 and group 2.
Frontiers in Immunology | www.frontiersin.org 7 September 2018 | Volume 9 | Article 2081
Gatto et al. SERPINB3 Administration Improves Lupus-Like Nephritis
Figure 4 shows representative kidney images with various
degrees of severity.
SERPINB3 Increases Treg Cells in MRL/lpr
Splenocytes
A remarkable increase in Treg cells was observed in T
lymphocytes isolated from spleen of SERPINB3-treated MRL/lpr
mice that was significantly higher than in controls at week 13 (%
mean ± SD: week 13: serpin 2.1%± 0.05 vs. PBS 1.4% ± 0.01,
p < 0.0001 Week 16: serpin 5.2± 0.7 vs. PBS 3.2± 0.8).
These findings were associated with a parallel decrease in Th17
cell number (% mean ± SD: week 13: serpin 0.5 ± 0.01 vs. PBS
1.7 ± 0.05, p < 0.0001; week 16 serpin 1.8% ± 0.8 vs. PBS
4.8%± 1.2), resulting in a significant reduction in the Th17:Treg
cell ratio in SERPINB3-treated mice compared with PBS-treated
mice (Figure 5).
DISCUSSION
SERPINB3 is a pleiotropic molecule found to be decreased on
the surface of B lymphocytes in SLE patients, being likely down-
regulated by IFN-α (12). SERPINB3 is deeply involved in the
control of apoptotic cell death (11, 20), which is markedly
impaired in patients with SLE (12), and was shown to up-regulate
TGF-β by autocrine and paracrine pathways (13, 14, 21), hinting
at a global pro-fibrogenic and anti-inflammatory effect. On the
basis of these findings, the present study has been addressed to
analyze the effects of restoration of SERPINB3 in murine models
of SLE.
NZB/W F1mice were chosen as a well-knownmodel of lupus-
like nephritis which allowed our experiments to focus on the
kidney, as the major target organ in SLE, while MRL/lpr mice
were chosen as additional model of systemic lupus-like disease,
resembling the complexity of human disease.
Mice injected with SERPINB3 showed a remarkable clinical
improvement in comparison with their control littermates,
with statistically significant delay in autoantibody appearance,
decrease in circulating autoantibody levels and increased
proteinuria-free and overall survival, suggesting that SERPINB3
can actually improve the course of the disease.
Interestingly, improvement in clinical and serological
parameters occurred in NZB/W F1mice both with the preventive
and the therapeutic approach, suggesting a protective potential
of SERPINB3 even when renal disease is already established.
Despite statistical significance was not reached for proteinuria
difference following the therapeutic approach, which may be due
FIGURE 4 | Representative images of mouse kidney with different extent of perivascular lesions (upper row), glomerular lesions (middle row) and tubular lesions (lower
row). Upper row, left to right: normal vasculature with patent artery and clear renal vein (magnification PAS40x), indicated by thick arrow; grade 3 infiltrate partially
surrounding the renal artery and bulging into the adjacent vein with sparing of connective tissue (HE20x), indicated by thick arrow; grade 5 perivascular infiltrate fully
surrounding the arcuate artery and invading both the vein (thick black arrows) and the adjacent connective tissue (thick dotted black arrows) (HE10x). Middle row, left
to right: near normal glomeruli (thick black arrows) with preserved basement membrane and urinary space (thick dotted black arrows) (PAS40x); intermediate
damaged glomeruli with reduced urinary space, thickened basement membrane (thick black arrows), cellular hyperplasia (thick dotted black arrows) and initial septal
fibrosis (thin dotted black arrows) (PAS40x); advanced glomerular damage with disappearance of glomerular structure, glomerular collapse and diffuse
glomerulosclerosis (two white thick arrows; single arrows pinpoints absence of urinary space due to collapse). Diffuse lymphocytic infiltrate is also present (PAS40x).
Lower row, left to right: near normal renal tubuli at the medullo-cortical interface with normal cell nuclei in a wide cytoplasm (thick black arrows) (PAS40x); initial
tubular dilation with flattened epithelial cells (thick dashed black arrows) with nuclei bulging into the tubular space (thick black arrows) (magnification PAS40x); severely
dilated tubuli (thick black arrows) with loss of normal architecture and widely represented protein casts (pink lakes) (thick dotted black arrows) (PAS10x). PAS, periodic
acid of Schiff; HE, hematoxylin-eosin.
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FIGURE 5 | Left to right. Proportion of Treg on total pool of CD4+, week 13 to week 16. Proportion of Th17 on total pool of CD4+, week 13 to week 16. Ratio of
Th17 cells to Treg cells (n = 3 per group). Results are the mean ± SD. ***P < 0.0001 vs. vehicle-treated controls.
to inadequate mice number, the decrease is apparent and likely
clinically relevant, as suggested by the improved survival after
therapeutic SERPINB3 administration.
Notably, decreased autoantibody and proteinuria levels,
associated with improved survival rates, were also confirmed in
MRL/lpr mice, thus suggesting a beneficial effect of SERPINB3
even in a heterogeneous system. As MRL/lpr mice are
characterized by amutation in the Fas domain, any counteracting
effect on uncontrolled apoptosis may have been responsible for
the observed benefits.
Although our study was focused on clinical variables and
outcomes and was not designed to evaluate tissue lesions, we
looked for changes in renal histology by analyzing renal sections
of mice sacrificed at given time points, which were chosen
according to time of autoantibody and proteinuria occurrence.
Interstitial perivascular lesions were quite similar among the
groups, which may be due to perivascular infiltrate appearing
early during nephritis course, making it unlikely to differ in the
intermediate or late stages of disease. Both mice strains treated
with SERPINB3 showed milder tubular and glomerular lesions,
with a lower proportion of severe tubular lesions, compared
to controls. These observations may have a clinical relevance,
though mice number was probably too low for statistical
analysis and the scoring system itself may have overlooked small
differences in disease severity. Indeed, although validated, any
semiquantative score for histological lesions bears the risk of
low sensitivity due to a range of values that embrace even very
different degrees of severity, thus sometimes flattening actual
clinical discrepancies.
Our results are in agreement with previous data obtained
with another member of the clade B serpins (OV-SERPINS),
namely ovalbumin (OVA), where OVA-injected NZB/NZW
F1 mice showed decreased anti-dsDNA antibody titers and
proteinuria levels, as well as a prolonged proteinuria-free survival
(Blank et al., personal communication). Since both OVA and
SERPINB3 were shown to improve the disease outcome in
murine lupus models, these might conceivably play a role in
maintaining immune homeostasis, and this novel function is in
line with the versatility of the serpin platform, recently described
involved in the regulation of diverse biological pathways (22).
Furthermore, other authors reported clinical improvement of
lupus-like disease and arthritis following administration of a
fragment of SERPINA1 and SERPINA3, respectively, which,
although belonging to different serpin subgroups, are sharing
similar mechanisms of action with OV-SERPINS (23, 24).
The mechanistic link between the known functions of
SERPINB3 and the improved clinical outcome observed in
treated mice has to be unraveled. It is so far well known that
the enrichment of the autoantigen pool due to deregulated
apoptosis may foster autoantibody production in human SLE (1).
Since SERPINB3 was shown to globally dampen the apoptotic
pathways, absence of SERPINB3 may result in enhanced
cellular turnover, with increased production and exposition of
cellular debris, which may in turn stimulate the generation of
autoantibodies toward nuclear antigens.
The increase of Treg cells, together with a parallel decrease
of Th17 cells, observed within the T cell pool from spleens
of MRL/lpr mice treated with SERPINB3 is a novel finding.
These regulatory cells are likely peripheral Treg dwelling in
tissues, which are known to have their FoxP3 expression induced
by changes in the surrounding microenvironment (25). Since
cytokines including TGFβ have some effects on plasticity of
T cells in the periphery (26), and given that TGFβ secretion
is promoted by SERPINB3 (13, 14), it may be speculated that
in lymphoid organs SERPINB3 may skew cells toward a more
tolerogenic phenotype. This hypothesis is in line with the finding
of decreased levels of IL-17 and IL-12 in MRL/lpr mice treated
with a fragment of SERPINA1 and in CD4+ cells incubated with
the same peptide (23). These observations suggest that SERPINS,
including SERPINB3, may influence the immune homeostasis
through shaping of the extracellular microenvironment.
Further studies will be required to investigate actual
mechanisms of action.
It should be reminded that perturbation of homeostatic
pathways is often involved in the development of autoimmunity
and in SLE immunomodulatory therapies targeting self-
molecules and cytokines are released or underway (27–30).
Actually, most of these drugs aim at reducing the hyperactivation
of physiological signals (31), while the case of SERPINB3 would
require the restoration of a normally activated pathway that
is instead downregulated in SLE. This is a new approach and
implies safety considerations.
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The present study has some limitations. The number of mice
included in the histological comparison was too low to draw firm
conclusion on potential effects of SERPINB3 on renal lesions,
which should then be included in a future outlook.
Moreover, exogenous administration of SERPINB3 to lupus-
prone mice causes increased concentrations of SERPINB3
in mice sera and tissues, therefore one may claim that
it does not mirror the physiological activity of SERPINB3.
However, different administration routes have been exploited
so far (20, 23) which do not overshadow the evidence
that SERPINS administration delay the onset of lupus-like
nephritis and firmly improve overall- and disease-free survival in
mice.
In summary, our data have shown that exogenous SERPINB3
induces a remarkable improvement in terms of both survival and
clinical outcome in lupus-prone mice. Particularly, SERPINB3-
injected mice developed a milder and markedly delayed renal
disease involvement. Notably, these findings were associated with
later appearance of nephritogenic antibodies in sera and their
levels were significantly lower than those found in controls.
Therefore, present clues suggest that this molecule may skew
cells in lymphoid organs toward a more tolerogenic phenotype,
counteracting the onset of severe lupus glomerulonephritis and
attenuating lupus phenotype.
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